CML10 Antibody

Introduction to CML10 Antibody

The term "CML10 Antibody" refers to a monoclonal antibody (clone CMS-10) targeting Nε-(carboxymethyl)lysine (CML), a major advanced glycation end product (AGE). AGEs form through non-enzymatic glycation and oxidation of proteins, lipids, or nucleic acids, contributing to aging and pathologies like diabetes, atherosclerosis, and neurodegenerative diseases . The CMS-10 clone is a mouse-derived IgG1 antibody developed for highly specific detection of CML-modified proteins in research and diagnostics .

Development and Specificity

CML10 Antibody (CMS-10) was generated by immunizing BALB/c mice with CML-keyhole limpet hemocyanin (CML-KLH). Hybridoma technology was employed to fuse splenic lymphocytes with myeloma cells, followed by stringent screening to ensure specificity for CML over structurally similar compounds like Nε-(carboxyethyl)lysine (CEL) .

Key Specificity Features:

• No cross-reactivity with CEL, distinguishing it from earlier polyclonal antibodies .

• Recognizes the single methyl group difference between CML and CEL .

• Validated against proteins modified by diverse aldehydes (e.g., glyoxal, glycolaldehyde) .

Applications in Research and Diagnostics

CML10 Antibody is widely used to study AGE accumulation in biological systems.

Biochemical Properties and Formulation

Role in Disease Pathogenesis

• Diabetes: CMS-10 detected CML in renal tubules of diabetic nephropathy patients and retinal tissues .

• Aging: CML-modified proteins were identified in lens tissues and skin elastin during normal aging .

• Neurodegeneration: CML colocalized with β-amyloid plaques in Alzheimer’s disease .

Validation Studies

• HPLC Correlation: CMS-10 reactivity strongly correlated with CML levels quantified via high-performance liquid chromatography (HPLC) .

• Oxidative Stress Markers: CML serves as a biomarker for oxidative damage, validated in models of atherosclerosis and hemodialysis-related amyloidosis .

Comparative Advantages

• Superior Specificity: Unlike the 6D12 clone, CMS-10 avoids cross-reactivity with CEL, enabling accurate CML quantification .

• Broad Reactivity: Detects CML formed via multiple pathways, including lipid peroxidation and glycoxidation .